Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1625
This examiner grants 74% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18250429 | 7-AZOLE SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | Final Rejection | MERCK SHARP & DOHME LLC |
| 18303910 | METHOD OF TREATING CANCER USING (TRI-TERT-BUTYLPHOSPHANE)GOLD(I) THIONE COMPLEXES | Non-Final OA | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS |
| 18287632 | Quinazoline Derivatives, Pharmaceutical Compositions, and Therapeutic Uses Related to Nox Inhibition | Non-Final OA | The Medical College of Wisconsin, Inc. |
| 18323240 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | Non-Final OA | Genentech, Inc. |
| 17999799 | BELVARAFENIB FOR USE IN CANCER TREATMENT | Non-Final OA | Genentech, Inc. |
| 17759814 | FIBROBLAST ACTIVATION PROTEIN (FAP) - TARGETED ANTIFIBROTIC THERAPY | Final Rejection | Purdue Research Foundation |
| 17765110 | USE OF VALERIC ACID DERIVATIVE IN TREATMENT OF DOWN'S SYNDROME | Final Rejection | XIAMEN UNIVERSITY |
| 18286185 | TREATMENT METHODS AND COMPOSITIONS COMPRISING PERAMPANEL | Non-Final OA | The Johns Hopkins University |
| 17997006 | COMPOSITIONS AND METHODS COMPRISING DENDRIMERS AND THERAPEUTIC AGENTS | Final Rejection | The Johns Hopkins University |
| 18263340 | METHODS OF TREATING CANCER WITH POZIOTINIB | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17553612 | USE OF AN RXR AGONIST IN TREATING HER2+ CANCERS | Final Rejection | Board of Regents, The University of Texas System |
| 17827041 | COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC STROKE | Final Rejection | UNM RAINFOREST INNOVATIONS |
| 18027785 | TRIAZINE COMPOUND, MATERIAL FOR ORGANIC LIGHT EMITTING DIODE, ELECTRON TRANSPORT MATERIAL FOR ORGANIC LIGHT EMITTING DIODE, AND ORGANIC LIGHT EMITTING DIODE | Non-Final OA | TOSOH CORPORATION |
| 17920645 | GPER PROTEOLYTIC TARGETING CHIMERAS | Final Rejection | University of Iowa Research Foundation |
| 17718052 | TARGETED TREATMENT OF CANCERS WITH DYSREGULATED FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING | Non-Final OA | Pharmacosmos Holding A/S |
| 18294129 | METHOD OF TREATING POSTTRAUMATIC STRESS DISORDER | Non-Final OA | Jazz Pharmaceuticals Ireland Limited |
| 18577383 | USE OF CHLOROGENIC ACID IN PREPARATION OF MEDICINE FOR TREATING CENTRAL NERVOUS SYSTEM TUMOR | Non-Final OA | SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTD. |
| 18548622 | Methods of Treatment with Selective CB2 Receptor Agonists | Non-Final OA | Arena Pharmaceuticals, Inc. |
| 18266102 | Eyedrops for Inhibiting Myopia Progression in Children and Screening Method for Inhibitor of Myopia Progression in Children | Non-Final OA | Tsubota Laboratory, Inc. |
| 18192313 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | Non-Final OA | Escient Pharmaceuticals, Inc. |
| 18001064 | INHIBITORS OF NEK7 KINASE | Final Rejection | Halia Therapeutics, Inc. |
| 18366187 | HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS | Non-Final OA | Ajax Therapeutics, Inc. |
| 18270624 | RAD51 BINDING INHIBITORS AND METHODS OF USE THEREOF | Non-Final OA | Sarissa Inc. |
| 18252741 | IMPROVED USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Non-Final OA | ORCOSA INC. |
| 17917734 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Non-Final OA | REMIX THERAPEUTICS INC. |
| 18248857 | HETEROCYCLIC GLP-1 AGONISTS | Non-Final OA | Gasherbrum Bio, Inc. |
| 18246931 | FORMULATIONS COMPRISING BOTANICAL EXTRACTS | Non-Final OA | APEX BIOTECH RESEARCH PTY LTD |
| 18028574 | Marker for determining anti-cancer effects of mitochondrial oxidative phosphorylation pathway inhibitor | Non-Final OA | NANJING SHIJIANG MEDICINE TECHNOLOGY CO., LTD |
| 18019885 | PROTEIN SECRETION INHIBITORS | Non-Final OA | KEZAR LIFE SCIENCES |
| 18008332 | NOVEL SMALL MOLECULES FOR TARGETED DEGRADATION OF UNTARGETABLE KRAS IN CANCER THERAPY | Non-Final OA | Pillai Universal LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy